A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

NCT02436928 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

H7N9 Influenza Vaccine

Interventions

BIOLOGICAL: AT-501 High Dose vaccine
BIOLOGICAL: AT-501 High Dose vaccine with Adjuvant
BIOLOGICAL: AT-501 Low Dose vaccine
BIOLOGICAL: AT-501 Low Dose vaccine with Adjuvant

Sponsor

Medigen Vaccine Biologics Corp.